Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.

Li C, Zang T, Wrobel K, Huang JT, Nabi G.

Anal Bioanal Chem. 2015 May;407(12):3393-404. doi: 10.1007/s00216-015-8569-6. Epub 2015 Feb 28.

PMID:
25724369
2.

Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.

Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL.

J Urol. 1994 Apr;151(4):909-13.

PMID:
7510346
3.

Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.

Tsoi TH, Chan CF, Chan WL, Chiu KF, Wong WT, Ng CF, Wong KL.

PLoS One. 2016 Sep 6;11(9):e0162217. doi: 10.1371/journal.pone.0162217. eCollection 2016.

4.

Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.

Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M.

J Urol. 1996 Nov;156(5):1691-5.

PMID:
8863572
5.

The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.

Nakayama K, Inoue T, Sekiya S, Terada N, Miyazaki Y, Goto T, Kajihara S, Kawabata S, Iwamoto S, Ikawa K, Oosaga J, Tsuji H, Tanaka K, Ogawa O.

PLoS One. 2014 Sep 18;9(9):e107234. doi: 10.1371/journal.pone.0107234. eCollection 2014.

6.

Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.

Adeola HA, Soares NC, Paccez JD, Kaestner L, Blackburn JM, Zerbini LF.

Proteomics Clin Appl. 2015 Jun;9(5-6):597-609. doi: 10.1002/prca.201400197. Epub 2015 May 3.

PMID:
25708745
7.

GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization.

Wu H, Liu T, Ma C, Xue R, Deng C, Zeng H, Shen X.

Anal Bioanal Chem. 2011 Aug;401(2):635-46. doi: 10.1007/s00216-011-5098-9. Epub 2011 May 29.

PMID:
21626193
8.

Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.

Neuhaus J, Schiffer E, von Wilcke P, Bauer HW, Leung H, Siwy J, Ulrici W, Paasch U, Horn LC, Stolzenburg JU.

PLoS One. 2013 Jun 24;8(6):e67514. doi: 10.1371/journal.pone.0067514. Print 2013.

9.

Furan and p-xylene as candidate biomarkers for prostate cancer.

Jiménez-Pacheco A, Salinero-Bachiller M, Iribar MC, López-Luque A, Miján-Ortiz JL, Peinado JM.

Urol Oncol. 2018 May;36(5):243.e21-243.e27. doi: 10.1016/j.urolonc.2017.12.026. Epub 2018 Feb 1.

PMID:
29395956
10.

Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.

Salido-Guadarrama AI, Morales-Montor JG, Rangel-Escareño C, Langley E, Peralta-Zaragoza O, Cruz Colin JL, Rodriguez-Dorantes M.

Mol Med Rep. 2016 Jun;13(6):4549-60. doi: 10.3892/mmr.2016.5095. Epub 2016 Apr 8.

11.

Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.

Minciu R, Dumache R, Gheorghe P, Daminescu L, Rogobete AF, Ionescu D.

Clin Lab. 2016;62(6):1183-6.

PMID:
27468582
12.

Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.

Coelho FF, Guimarães FL, Cabral WL, Salles PG, Mateo EC, Nogueira e Nogueira LM, Fonseca CE, Gomes KB.

Genet Mol Res. 2015 Oct 28;14(4):13519-31. doi: 10.4238/2015.October.28.13.

13.

Determination of amino acids in urine of patients with prostate cancer and benign prostate growth.

Sroka WD, Boughton BA, Reddy P, Roessner U, Słupski P, Jarzemski P, Dąbrowska A, Markuszewski MJ, Marszałł MP.

Eur J Cancer Prev. 2017 Mar;26(2):131-134. doi: 10.1097/CEJ.0000000000000248.

PMID:
27222937
14.

Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer.

Sequeiros T, Rigau M, Chiva C, Montes M, Garcia-Grau I, Garcia M, Diaz S, Celma A, Bijnsdorp I, Campos A, Di Mauro P, Borrós S, Reventós J, Doll A, Paciucci R, Pegtel M, de Torres I, Sabidó E, Morote J, Olivan M.

Oncotarget. 2017 Jan 17;8(3):4960-4976. doi: 10.18632/oncotarget.13634.

15.

Multigene methylation analysis for detection and staging of prostate cancer.

Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.

Clin Cancer Res. 2005 Sep 15;11(18):6582-8.

16.

Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.

Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA.

BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.

17.

Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling.

Cheng HL, Huang HJ, Ou BY, Chow NH, Chen YW, Tzai TS, Wu CJ, Chen SH.

Proteomics Clin Appl. 2011 Apr;5(3-4):121-32. doi: 10.1002/prca.201000011. Epub 2011 Feb 15.

PMID:
21322116
18.
19.

Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.

Yan C, Kim YH, Kang HW, Seo SP, Jeong P, Lee IS, Kim D, Kim JM, Choi YH, Moon SK, Yun SJ, Kim WJ.

J Korean Med Sci. 2015 Dec;30(12):1784-92. doi: 10.3346/jkms.2015.30.12.1784. Epub 2015 Nov 30.

20.

Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.

Wymenga LF, Groenier K, Schuurman J, Boomsma JH, Elferink RO, Mensink HJ.

BJU Int. 2001 Aug;88(3):231-5.

Supplemental Content

Support Center